Drug
Mezagitamab
Mezagitamab: highest development phase Phase 3, developed by Takeda, United Therapeutics. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mezagitamab NCT06722235 | Phase 3 | Immune Thrombocytopenic Purpura (ITP) |
| Mezagitamab NCT06948318 | Phase 3 | Immune Thrombocytopenic Purpura (ITP) |
| Mezagitamab NCT06963827 | Phase 3 | Kidney Disease |
| Mezagitamab NCT07613359 | Phase 2 | Antibody-Mediated Rejection (AMR) |
| Mezagitamab NCT03439280 | Phase 1/2 | Relapsed/Refractory |
Latest
No recent events.
Follow Mezagitamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.